# Otezla (apremilast) PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/apremilast

> The FDA approved Otezla (apremilast), sponsored by AMGEN INC (AMGN), on August 29, 2025.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, quarter only, month only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Key facts

| Field | Value |
| --- | --- |
| Drug | Otezla (apremilast) |
| Codes | AMG-407, CC-10004 |
| Sponsor | AMGEN INC (AMGN) https://sec-api.dev/companies/amgn/catalysts |
| Indications | [Plaque Psoriasis](https://sec-api.dev/indications/plaque-psoriasis), [Active Juvenile Psoriatic Arthritis](https://sec-api.dev/indications/active-juvenile-psoriatic-arthritis), [Psoriasis](https://sec-api.dev/indications/psoriasis), [Behçet Disease](https://sec-api.dev/indications/behcet-disease) |
| Modality |  |
| FDA designations | priority review |

## Timeline

### April 10, 2020: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "NDA205437 SUPPL-8 (Efficacy): submission_status AP, submission_status_date 20200410, review_priority STANDARD; sponsor_name AMGEN INC; product OTEZLA (APREMILAST)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA205437%22

### December 20, 2021: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "NDA205437 SUPPL-11 (Efficacy): submission_status AP, submission_status_date 20211220, review_priority STANDARD; sponsor_name AMGEN INC; product OTEZLA (APREMILAST)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA205437%22

### July 20, 2023: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "NDA205437 SUPPL-12 (Efficacy): submission_status AP, submission_status_date 20230720, review_priority STANDARD; sponsor_name AMGEN INC; product OTEZLA (APREMILAST)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA205437%22

### April 25, 2024: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "NDA205437 SUPPL-13 (Efficacy): submission_status AP, submission_status_date 20240425, review_priority PRIORITY; sponsor_name AMGEN INC; product OTEZLA (APREMILAST)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA205437%22

### July 23, 2025: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "NDA205437 SUPPL-14 (Efficacy): submission_status AP, submission_status_date 20250723, review_priority STANDARD; sponsor_name AMGEN INC; product OTEZLA (APREMILAST)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA205437%22

### August 29, 2025: FDA approval

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "NDA210745 ORIG-2 (Type 5 - New Formulation or New Manufacturer): submission_status AP, submission_status_date 20250829, review_priority STANDARD; sponsor_name AMGEN INC; product OTEZLA (APREMILAST)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA210745%22
- openFDA Drugs@FDA: "NDA210745 ORIG-1 (Type 5 - New Formulation or New Manufacturer): submission_status AP, submission_status_date 20250829, review_priority STANDARD; sponsor_name AMGEN INC; product OTEZLA (APREMILAST)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA210745%22

### October 30, 2025: primary completion

- Status: completed. Date confidence: exact. Stage: 3. Indication: Psoriasis.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT04175613 (A Long-term Extension Study of Apremilast (CC-10004) in Pediatric Subjects From 6 Through 17 Years of Age With Moderate to Severe Plaque Psoriasis): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-10-30 (ACTUAL); Lead Sponsor Amgen." https://clinicaltrials.gov/study/NCT04175613

### November 20, 2025: primary completion

- Status: completed. Date confidence: exact. Stage: 3. Indication: Plaque Psoriasis.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT05565560 (A Study to Assess the Efficacy and Safety of Apremilast in Japanese Pediatric Participants With Moderate to Severe Plaque Psoriasis): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-11-20 (ACTUAL); Lead Sponsor Amgen." https://clinicaltrials.gov/study/NCT05565560

### August 12, 2026: primary completion

- Status: completed. Date confidence: exact. Stage: 3. Indication: Plaque Psoriasis.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06088199 (A Study of Apremilast in Pediatric Participants in Children With Mild to Moderate Plaque Psoriasis): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2026-08-12 (ACTUAL); Lead Sponsor Amgen." https://clinicaltrials.gov/study/NCT06088199

### Aug to Nov 2026: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Plaque Psoriasis.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06088199 (A Study of Apremilast in Pediatric Participants in Children With Mild to Moderate Plaque Psoriasis): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2026-08-12 (ACTUAL); Lead Sponsor Amgen." https://clinicaltrials.gov/study/NCT06088199

### Mar to Jun 2028: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Active Juvenile Psoriatic Arthritis.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT04804553 (Apremilast Pediatric Study in Children With Active Juvenile Psoriatic Arthritis): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-03-21 (ESTIMATED); Lead Sponsor Amgen." https://clinicaltrials.gov/study/NCT04804553

### March 2028: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: Active Juvenile Psoriatic Arthritis.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT04804553 (Apremilast Pediatric Study in Children With Active Juvenile Psoriatic Arthritis): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-03-21 (ESTIMATED); Lead Sponsor Amgen." https://clinicaltrials.gov/study/NCT04804553

### Feb to May 2030: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Behçet Disease.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT04528082 (Apremilast Pediatric Study in Children With Active Oral Ulcers Associated With Behçet's Disease): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2030-02-07 (ESTIMATED); Lead Sponsor Amgen." https://clinicaltrials.gov/study/NCT04528082

### February 2030: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: Behçet Disease.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT04528082 (Apremilast Pediatric Study in Children With Active Oral Ulcers Associated With Behçet's Disease): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2030-02-07 (ESTIMATED); Lead Sponsor Amgen." https://clinicaltrials.gov/study/NCT04528082

## Same indication

- [Sotyktu (deucravacitinib)](https://sec-api.dev/pdufa/deucravacitinib) (BMY)
- [Dusquetide](https://sec-api.dev/pdufa/dusquetide) (SNGX)
- [Envudeucitinib](https://sec-api.dev/pdufa/envudeucitinib) (ALMS)
- [Tremfya (guselkumab)](https://sec-api.dev/pdufa/guselkumab) (JNJ)
- [Hypericin](https://sec-api.dev/pdufa/hypericin) (SNGX)
- [Taltz (ixekizumab)](https://sec-api.dev/pdufa/ixekizumab) (LLY)
- [Open-label envudeucitinib](https://sec-api.dev/pdufa/open-label-envudeucitinib) (ALMS)
- [ORKA-001](https://sec-api.dev/pdufa/orka-001) (ORKA)
- [Orka-001 induction dose](https://sec-api.dev/pdufa/orka-001-induction-dose) (ORKA)
- [ORKA-002](https://sec-api.dev/pdufa/orka-002) (ORKA)
- [Piclidenoson](https://sec-api.dev/pdufa/piclidenoson) (CANF)
- [Skyrizi® (risankizumab)](https://sec-api.dev/pdufa/risankizumab) (ABBV)
- [TAK-279](https://sec-api.dev/pdufa/tak-279) (TAK)
- [Tapinarof cream, 1%](https://sec-api.dev/pdufa/tapinarof-cream-1) (OGN)
- [WEZLANA® (ustekinumab)](https://sec-api.dev/pdufa/ustekinumab) (JNJ)
- [Zasocitinib](https://sec-api.dev/pdufa/zasocitinib) (TAK)
- [Zl-1102 1% w/w gel bid for 16 weeks](https://sec-api.dev/pdufa/zl-1102-1-w-w-gel-bid-for-16-weeks) (ZLAB)

Calendar months: [March 2028](https://sec-api.dev/fda-calendar/2028-03)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/apremilast.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Otezla (apremilast) PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/apremilast

```bibtex
@misc{secapidev_pdufa_apremilast_20261116,
  title        = {Otezla (apremilast) PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/apremilast}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_apremilast_20261116","title":"Otezla (apremilast) PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/apremilast","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
